Commentary: targeting myelodysplastic syndromes

Leuk Res. 2002 Aug;26(8):703. doi: 10.1016/s0145-2126(02)00024-3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents
  • Cytokines / antagonists & inhibitors
  • Drug Design
  • Humans
  • Myelodysplastic Syndromes / drug therapy*
  • Myelodysplastic Syndromes / etiology
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antineoplastic Agents
  • Cytokines
  • Tumor Necrosis Factor-alpha